Wat is de prijs voor Psyence Biomedical Ltd. (PBM)

Het prijs van Psyence Biomedical Ltd. (PBM) is $3.20

Wat is de marktkapitalisatie voor Psyence Biomedical Ltd. (PBM)

Marktkapitalisatie voorPsyence Biomedical Ltd. (PBM) is $60.86K

Psyence Biomedical Ltd. (PBM) Prijs en Marktkapitalisatie

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Prijs voor PBM	Aandeel B	Marktkapitalisatie van B	uitslagen
$286,146,304 $60.86K	NVDA	$5.442T	+8,942,071,889.08%
$234,222,351 $60.86K	AAPL	$4.455T	+7,319,448,371.78%
$219,727,536 $60.86K	GOOG	$4.179T	+6,866,485,403.55%
$193,125,207 $60.86K	MSFT	$3.673T	+6,035,162,611.47%
$150,522,481 $60.86K	AMZN	$2.863T	+4,703,827,446.67%

Prijs voor PBM

Aandeel B

Marktkapitalisatie van B

uitslagen

$286,146,304 $60.86K